In a research note issued to investors, span class=”tipranks-expert-name”> Chris Schott at J.P. Morgan Reiterated their Buy rating on Valeant Pharmaceuticals Intl Inc (NYSEVRX).
Advertisement
The stock has more than doubled in the last 12 months. The disclosure for this purchase can be found here. Analysts at Guggenheim reiterated a “buy” rating and set a $300.00 price target on shares of Valeant Pharmaceuticals Intl in a research note on Friday.
Valeant Pharmaceuticals Intl (NYSE:VRX) traded down 0.601% on Monday, hitting $239.145. (NYSE:VRX): On Tuesday heightened volatility was witnessed in Valeant Pharmaceuticals global, Inc. The heightened volatility saw the trading volume jump to 1,591,865 shares. Valeant Pharmaceuticals Intl has a 52 week low of $106.00 and a 52 week high of $253.68. Finally, analysts at Scotiabank reiterated an “outperform” rating and set a $290.00 price target on shares of Valeant Pharmaceuticals Intl in a research note on Sunday, July 12th. Three equities research analysts have rated the stock with a hold rating and twenty-two have assigned a buy rating to the stock. The stock’s 50-day moving average is $231.66 and its 200-day moving average is $203.63.
The average broker recommendation is arithmetical average of the individual ratings contributed by sell-side analysts to produce a Consensus Analyst Rating for each stock. The company has a market cap of $81.73 billion and a P/E ratio of 81.39.
For the current quarter ending in September, Valeant expects its per-share earnings to range from $2.60 to $2.70.
Non-adjusted results for the quarter that ended on June 30 showed a loss of US$53 million, or 15 cents a share, compared with US$125.8 million, or 37 cents a share a year ago.
The Company is engaged in developing, manufacturing, and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices), which are marketed directly or indirectly in over 100 countries. On Thursday, Valeant said it is acquiring Commonwealth Laboratories Inc’s Canadian and U.S. business.
Advertisement
Valeant had forecast per-share earnings of .40 to .50 and revenue of .45 billion to .55 billion for the quarter. Valeant Pharmaceuticals Intl shares have increased 79.95% in the last 200 days, while the Standard & Poor’s 500 index has increased 7.83% for the same time. Within its U.S. Dermatology segment and Branded Generic – Europe segment the Company generates service revenue from contract services in the areas of dermatology and topical medication. Moreover, Ruane Cunniff & Goldfarb Inc have 32.06% of their stock exposure invested in the company for 34.09M shares.
